Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Cited by (1,053)

Items 101–200 of 1,053

1. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
   Patrick Alexander Ott, Frank Stephen Hodi, Caroline Robert · 2013 · Clinical Cancer Research
2. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
   Julien Haroche, Frédéric Charlotte, Laurent Arnaud, Andreas von Deimling, Zofia Hélias‐Rodzewicz, B. Hervier, Fleur Cohen Aubart, David Launay, Annette Lesot, Karima Mokhtari et al. · 2012 · Blood
3. NRAS mutation status is an independent prognostic factor in metastatic melanoma
   John Andrew Jakob, Roland L. Bassett, Chaan S. Ng, Jonathan L. Curry, Richard Wayne Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim et al. · 2011 · Cancer
4. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
   McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew et al. · 2018 · The Lancet Oncology
5. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
   James S. Wilmott, Georgina Venetia Long, Julie R. Howle, Lauren Elaine Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, Richard A. Scolyer · 2011 · Clinical Cancer Research
6. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
   Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve‐Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff A. Otto, Kristina W. Brennan, Rajmohan Murali et al. · 2014 · Nature Communications
7. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
   Hubing Shi, Gatien Moriceau, Xiangju Kong, Mi‐Kyung Lee, Hane Lee, Richard Chikara Koya, Charles Ng, Thinle Chodon, Richard A. Scolyer, Kimberly Brown Dahlman et al. · 2012 · Nature Communications
8. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
   Müller, Judith, Krijgsman, Oscar, Tsoi, Jennifer, Robert, Lidia, Hugo, Willy, Song, Chunying, Kong, Xiangju, Possik, Patricia A., Cornelissen-Steijger, Paulien D. M., Foppen, Marnix H Geukes et al. · 2014 · Nature Communications
9. The emerging clinical relevance of genomics in cancer medicine
   Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
10. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto, Paolo A, Schadendorf, Dirk, Berking, Carola, Agarwala, Sanjiv S, van Herpen, Carla ML, Queirolo, Paola, Blank, Christian U, Hauschild, Axel, Beck, J Thaddeus, St-Pierre, Annie et al. · 2013 · The Lancet Oncology
11. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
    Sameek Roychowdhury, Matthew K. Iyer, Dan R. Robinson, Robert J. Lonigro, Yi-Mi Wu, Xuhong Cao, Shanker Kalyana Sundaram, Lee T. Sam, O. Alejandro Balbin, Michael J. Quist et al. · 2011 · Science Translational Medicine
12. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
    Caunt, Christopher J., Sale, Matthew J., Smith, Paul D., Cook, Simon J. · 2015 · Nature Reviews Cancer
13. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    Josep Maria Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn · 2015 · Nature Reviews Clinical Oncology
14. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
    Hata, Aaron N., Engelman, Jeffrey A., Faber, Anthony C. · 2015 · Cancer Discovery
15. Evolutionary dynamics of cancer in response to targeted combination therapy
    Ivana Božić, Johannes G. Reiter, Benjamin Allen, Tibor Antal A, Krishnendu Chatterjee, Preya Shah, Yo Sup Moon, Amin Yaqubie, Nicole E. Kelly, Dung Thi Le et al. · 2013 · eLife
16. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
    Vivek Asati, Debarshi Kar Mahapatra, Sanjay Kumar Bharti · 2016 · European Journal of Medicinal Chemistry
17. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
18. Guidelines of care for the management of primary cutaneous melanoma
    Christopher Keram Bichakjian, Allan C. Halpern, Timothy M. Johnson, Antoinette F. Hood, James M. Grichnik, Susan M. Swetter, Hensin Tsao, Victoria Barbosa, Tsu‐Yi Chuang, Madeleine A. Duvic et al. · 2011 · Journal of the American Academy of Dermatology
19. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
    Hirata, Eishu, Girotti, Maria Romina, Viros, Amaya, Hooper, Steven, Spencer-Dene, Bradley, Matsuda, Michiyuki, Larkin, James, Marais, Richard, Sahai, Erik · 2015 · Cancer Cell
20. CGCG clinical practice guidelines for the management of adult diffuse gliomas
    Tao Jiang, Ying Qing Mao, Wenbin Ma, Qing Mao, Yongping You, Xuejun Yang, Chuanlu Jiang, Chunsheng Kang, Xuejun Li, Ling Chen et al. · 2016 · Cancer Letters
21. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
    Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saïag, Mark Ross Middleton, Lars Bastholt, Jean‐Jacques Grob, Josep Malvehy, Julia Newton‐Bishop, Alexander Stratigos et al. · 2016 · European Journal of Cancer
22. Molecular and histological correlations in liver cancer
    Julien Caldéraro, Marianne Ziol, Valérie Paradis, Jessica Zucman‐Rossi · 2019 · Journal of Hepatology
23. Cutaneous melanoma: From pathogenesis to therapy (Review)
    Giulia Costanza Leonardi, Luca Falzone, Rossella Salemi, Antonio Zanghì, Demetrios A. Spandidos, James Andrew McCubrey, Saverio Candido, Massimo Libra · 2018 · International Journal of Oncology
24. Discovery of small molecule cancer drugs: Successes, challenges and opportunities
    Swen Hoelder, Paul Andrew Clarke, Paul Workman · 2012 · Molecular Oncology
25. Tumor adaptation and resistance to RAF inhibitors
    Lito, Piro, Rosen, Neal, Solit, David B · 2013 · Nature Medicine
26. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
    Lito, Piro, Pratilas, Christine A., Joseph, Eric W., Tadi, Madhavi, Halilovic, Ensar, Zubrowski, Matthew, Huang, Alan, Wong, Wai Lin, Callahan, Margaret K., Merghoub, Taha et al. · 2012 · Cancer Cell
27. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
    Jordi Ahnert Rodon, Jean‐Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Maria Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña et al. · 2019 · Nature Medicine
28. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
    Meyer, Christiane, Cagnon, Laurène, Costa-Nunes, Carla M., Baumgaertner, Petra, Montandon, Nicole, Leyvraz, Loredana, Michielin, Olivier, Romano, Emanuela, Speiser, Daniel E. · 2014 · Cancer Immunology Immunotherapy
29. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Evan J. Lipson, Charles G. Drake · 2011 · Clinical Cancer Research
30. Precision medicine for cancer with next-generation functional diagnostics
    Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T. · 2015 · Nature Reviews Cancer
31. Emerging insights into the molecular and cellular basis of glioblastoma
    Gavin P. Dunn, Mikael L. Rinne, Jill Wykosky, Giannicola Genovese, Steven N. Quayle, Ian F. Dunn, Pankaj Kumar Agarwalla, Milan G. Chheda, Benito Campos, Alan Wang et al. · 2012 · Genes & Development
32. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
    Ignacio Garrido‐Laguna, Manuel M. Hidalgo · 2015 · Nature Reviews Clinical Oncology
33. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
34. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
    Matthew Dankner, April A. N. Rose, Shivshankari Rajkumar, Peter M. Siegel, Ian R. Watson · 2018 · Oncogene
35. Cutaneous melanoma
    Alexander M.M. Eggermont, Alan Spatz, Caroline Robert · 2013 · The Lancet
36. Prognostic factors for survival in melanoma patients with brain metastases
    Michael A. Davies, Ping Liu, Susan E McIntyre, Kevin B. Kim, Nicholas Papadopoulos, Wen‐Jen Hwu, Patrick Hwu, Agop Y. Bedikian · 2010 · Cancer
37. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
    Helen Rizos, Alexander Maxwell Menzies, Gulietta M. Pupo, Matteo Salvatore Carlino, Carina Fung, Jessica Hyman, Lauren Elaine Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd et al. · 2014 · Clinical Cancer Research
38. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
    Gerald Steven Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas James DeMarini, Peng Gang Sun, Christopher H. Moy, Stephen A. Szabo, Lori Roadcap et al. · 2012 · The Lancet Oncology
39. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
    Burt Nabors, Jana Portnow, Manmeet Singh Ahluwalia, Joachim M. Baehring, Henry Brem, Steven S. Brem, Nicholas Arthur Butowski, Jian Li Campian, Stephen W. Clark, Andrew J. Fabiano et al. · 2020 · Journal of the National Comprehensive Cancer Network
40. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
    Apostolia Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald Steven Falchook, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra et al. · 2012 · Clinical Cancer Research
41. G-quadruplexes: a promising target for cancer therapy
    Nils Kosiol, Stefan Juranek, Peter Brossart, Annkristin Heine, Katrin Paeschke · 2021 · Molecular Cancer
42. A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
    David Joseph Konieczkowski, Cory M. Johannessen, Omar O. Abudayyeh, Jong Wook Kim, Zachary Aaron Cooper, Adriano Piris, Dennie Tompers Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq et al. · 2014 · Cancer Discovery
43. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey et al. · 2013 · Journal of Clinical Oncology
44. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer
    Jens G. Lohr, Viktor A. Adalsteinsson, Kristian Cibulskis, Atish Dipankar Choudhury, Mara W. Rosenberg, Peter Cruz‐Gordillo, Joshua M. Francis, Cheng-Zhong Zhang, Alex K. Shalek, Rahul Satija et al. · 2014 · Nature Biotechnology
45. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
    Li, Qing, Geng, Shan, Luo, Hao, Wang, Wei, Mo, Ya-Qi, Luo, Qing, Wang, Lu, Song, Guan-Bin, Sheng, Jian-Peng, Xu, Bo · 2024 · Signal Transduction and Targeted Therapy
46. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
    Julien Haroche, Fleur Cohen Aubart, Jean‐François Emile, Laurent Arnaud, Philippe Maksud, Frédéric Charlotte, Philippe Cluzel, Aurélie Drier, B. Hervier, Neïla Benameur et al. · 2012 · Blood
47. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
    Marianna Zolotovskaia, Maxim Sorokin, Anna A. Emelianova, Nikolay Borisov, Denis Kuzmin, Pieter Borger, Andrew Garazha, Anton A. Buzdin · 2019 · Frontiers in Pharmacology
48. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
49. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla Kaliopi Brastianos, Amaro N Taylor-Weiner, Peter E. Manley, Robert T. Jones, Dora C. Dias-Santagata, Aaron R. Thorner, Michael S. Lawrence, Fausto J. Rodríguez, Lindsay A. Bernardo, Laura Schubert et al. · 2014 · Nature Genetics
50. Circumventing cancer drug resistance in the era of personalized medicine
    Garraway, Levi A., Jänne, Pasi A. · 2012 · Cancer Discovery
51. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
    James Larkin, David R. Minor, Sandra P. D’Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. Lao et al. · 2017 · Journal of Clinical Oncology
52. Cancer biomarker discovery and validation.
    Nicolas Goossens, Shigeki Nakagawa, Xiaochen Sun, Yujin Hoshida · 2015 · PubMed
53. Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study
    Hainsworth, John D., Meric-Bernstam, Funda, Swanton, Charles, Hurwitz, Herbert, Spigel, David R., Sweeney, Christopher, Burris, Howard A., Bose, Ron, Yoo, Bongin, Stein, Alisha et al. · 2018 · Journal of Clinical Oncology
54. Oncogenic KRAS signalling in pancreatic cancer
    Serap EŞER, Angelika Schnieke, Günter Schneider, Dieter Saur · 2014 · British Journal of Cancer
55. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
    Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Maria Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Lukasz Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà et al. · 2017 · The Lancet Oncology
56. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
    Jimin Yuan, Xiaoduo Dong, Jiajun Yap, Jiancheng Hu · 2020 · Journal of Hematology & Oncology
57. Therapy-induced tumour secretomes promote resistance and tumour progression
    Anna C. Obenauf, Yilong Zou, Andrew L. Ji, Sakari Vanharanta, Weiping Shu, Hubing Shi, Xiangju Kong, Marcus Bosenberg, Thomas Wiesner, Neal X. Rosen et al. · 2015 · Nature
58. Melanoma: from mutations to medicine
    Tsao, Hensin, Chin, Lynda, Garraway, Levi A., Fisher, David E. · 2012 · Genes & Development
59. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
    Maria Clemence Schwaederle, Melissa M. Zhao, J. Jack Lee, Alexander M.M. Eggermont, Richard L. Schilsky, John M. Mendelsohn, Vladimir Lazar, Razelle Kurzrock · 2015 · Journal of Clinical Oncology
60. Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
    Morris, John C., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Reiss, Michael, Hsu, Frank J., Berzofsky, Jay A., Lawrence, Donald P. · 2014 · PLoS ONE
61. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
    Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle et al. · 2015 · Journal of Clinical Oncology
62. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
    Jiang, Xiaofeng, Zhou, Jun, Giobbie-Hurder, Anita, Wargo, Jennifer, Hodi, F. Stephen · 2013 · Clinical Cancer Research
63. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
64. MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
    Wagle, Nikhil, Van Allen, Eliezer M., Treacy, Daniel J., Frederick, Dennie T., Cooper, Zachary A., Taylor-Weiner, Amaro, Rosenberg, Mara, Goetz, Eva M., Sullivan, Ryan J., Farlow, Deborah N. et al. · 2014 · Cancer Discovery
65. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
    Peter A. Prieto, James Chih‐Hsin Yang, Richard Mark Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald Edward White, Catherine L. Levy, Steven A. Rosenberg, Giao Q. Phan · 2012 · Clinical Cancer Research
66. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
    Kevin B. Kim, Richard F. Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey Alan Sosman, Leslie Anne Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu et al. · 2012 · Journal of Clinical Oncology
67. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
    McMillin, Douglas W., Negri, Joseph M., Mitsiades, Constantine S. · 2013 · Nature Reviews Drug Discovery
68. Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
    John R. Prensner, Mark A. Rubin, John Thomas Wei, Arul M. Chinnaiyan · 2012 · Science Translational Medicine
69. BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
    Maria Colombino, Mariaelena Capone, Amelia Lissia, Antonio Cossu, Corrado Rubino, Vincenzo DE GIORGI, Daniela Massi, Ester Fonsatti, Stefania Staibano, Oscar Nappi et al. · 2012 · Journal of Clinical Oncology
70. Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
    Ma, Xiao-Hong, Piao, Sheng-Fu, Dey, Souvik, Mcafee, Quentin, Karakousis, Giorgos, Villanueva, Jessie, Hart, Lori S., Levi, Samuel, Hu, Janice, Zhang, Gao et al. · 2014 · Journal of Clinical Investigation
71. Exploiting the curative potential of adoptive T‐cell therapy for cancer
    Hinrichs, Christian S., Rosenberg, Steven A. · 2014 · Immunological Reviews
72. An overview of targeted cancer therapy
    V. Vijaya Padma · 2015 · Biomedicine
73. Institutional implementation of clinical tumor profiling on an unselected cancer population
    Sholl, Lynette M., Do, Khanh, Shivdasani, Priyanka, Cerami, Ethan, Dubuc, Adrian M., Kuo, Frank C., Garcia, Elizabeth P., Jia, Yonghui, Davineni, Phani, Abo, Ryan P. et al. · 2016 · JCI Insight
74. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
    Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Michelle Medina, Harriet M. Kluger, Sajeve Samuel Thomas, Evidio Domingo‐Musibay, Anna C. Pavlick, Eric D. Whitman et al. · 2021 · Journal of Clinical Oncology
75. Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward, Stephen E. Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith · 2020 · Chemical Reviews
76. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
    Johannessen, Cory M., Johnson, Laura A., Piccioni, Federica, Townes, Aisha, Frederick, Dennie T., Donahue, Melanie K., Narayan, Rajiv, Flaherty, Keith T., Wargo, Jennifer A., Root, David E. et al. · 2013 · Nature
77. Targeting cancer with kinase inhibitors
    Stefan David Gross, Rami Rahal, Nicolas Stransky, Christoph Lengauer, Klaus P. Hoeflich · 2015 · Journal of Clinical Investigation
78. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
    Marie‐Luise Berres, Karen Phaik Har Lim, Tricia Peters, Jeremy G. Price, Hitoshi Takizawa, Hélène Salmon, Juliana Idoyaga, Albert Ruzo, Philip J. Lupo, John M. Hicks et al. · 2014 · The Journal of Experimental Medicine
79. Abscopal effects of radiation therapy: A clinical review for the radiobiologist
    Shankar Siva, Michael Patrick MacManus, Roger F. Martin, Olga A. Martin · 2013 · Cancer Letters
80. MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
    Huang, Sidong, Hölzel, Michael, Knijnenburg, Theo, Schlicker, Andreas, Roepman, Paul, McDermott, Ultan, Garnett, Mathew, Grernrum, Wipawadee, Sun, Chong, Prahallad, Anirudh et al. · 2012 · Cell
81. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
    Lee M. Ellis, David S. Bernstein, Emile E. Voest, Jordan D. Berlin, Daniel J. Sargent, Patricia Cortazar, Elizabeth S. Garrett-Mayer, Roy S. Herbst, Rogério Lilenbaum, Camelia S. Sima et al. · 2014 · Journal of Clinical Oncology
82. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, William Edgar Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan Courtney Fields, Martin D. Fleming et al. · 2019 · Journal of the National Comprehensive Cancer Network
83. Clinical practice guidelines for the management of adult diffuse gliomas
    Tao Jiang, Do‐Hyun Nam, Zvi Ram, Wai Sang Poon, Jiguang Wang, Damdindorj Boldbaatar, Ying Qing Mao, Wenbin Ma, Qing Mao, Yongping You et al. · 2020 · Cancer Letters
84. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma
    Alexander Maxwell Menzies, Lauren Elaine Haydu, Lydia Visintin, Matteo Salvatore Carlino, Julie R. Howle, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, Georgina Venetia Long · 2012 · Clinical Cancer Research
85. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Ryan Joseph Sullivan, Jeffrey R. Infante, Filip Jankú, Deborah Jean Lee Wong, Jeffrey Alan Sosman, Vicki Leigh Keedy, Manish R. Patel, Geoffrey Ira Shapiro, James Walter Mier, Anthony W. Tolcher et al. · 2017 · Cancer Discovery
86. Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
    Fei‐Fei Liu, Xiaotong Yang, Meiyu Geng, Min Huang · 2018 · Acta Pharmaceutica Sinica B
87. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
    Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary E. Guckert, Dirk Schadendorf, Richard F. Kefford, Jean‐Jacques Grob et al. · 2013 · Journal of Clinical Oncology
88. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
    Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje et al. · 2018 · Blood
89. Cancer immunotherapy – revisited
    Willem Joost Lesterhuis, John B.A.G. Haanen, Cornelis J.A. Punt · 2011 · Nature Reviews Drug Discovery
90. The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
    Jennifer A. Lo, David E. Fisher · 2014 · Science
91. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
    Jonathan E. Rosenberg, Richard Martin Bambury, Eliezer M. Van Allen, Harry A. Drabkin, Primo N. Lara, Andrea Lynne Harzstark, Nikhil Wagle, Robert A. Figlin, Gregory W. Smith, Levi A. Garraway et al. · 2013 · Investigational New Drugs
92. Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
    Inês Pires da Silva, Anne Gallois, Sonia Jiménez-Baranda, Shaukat Ali Khan, Ana Carrizosa Anderson, Vijay Kumar Kuchroo, Iman Osman, Nina Bhardwaj · 2014 · Cancer Immunology Research
93. New perspectives for targeting RAF kinase in human cancer
    Karoulia, Zoi, Gavathiotis, Evripidis, Poulikakos, Poulikos I. · 2017 · Nature Reviews Cancer
94. Tumor Microenvironment and Differential Responses to Therapy
    Hirata, Eishu, Sahai, Erik · 2017 · Cold Spring Harbor Perspectives in Medicine
95. Cell-Based Therapeutics: The Next Pillar of Medicine
    Michael Andrew Fischbach, Jeffrey A. Bluestone, Wendell A. Lim · 2013 · Science Translational Medicine
96. Limits to Personalized Cancer Medicine
    Ian F. Tannock, John A. Hickman · 2016 · New England Journal of Medicine
97. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis
    Pencheva, Nora, Tran, Hien, Buss, Colin, Huh, Doowon, Drobnjak, Marija, Busam, Klaus, Tavazoie, Sohail F. · 2012 · Cell
98. Combine and conquer: challenges for targeted therapy combinations in early phase trials
    Lopez, Juanita S., Banerji, Udai · 2017 · Nature Reviews Clinical Oncology
99. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
    Alexander Edward Dela Cruz Drilon, Zishuo I. Hu, Gillianne Geet Yi Lai, Daniel S.W. Tan · 2017 · Nature Reviews Clinical Oncology
100. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
     Liang Cheng C, Antonio Lopez-beltran B, Francesco Massari, Gregory T. MacLennan, Rodolfo Montironi · 2017 · Modern Pathology